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1. Introduction 
AAA is the thirteenth cause of death in UK accounting for 1.2% of male and 0.6 of female 
mortality, and the third cause of sudden death after coronary artery disease and stroke. [1-3] 
Abdominal aortic aneurysms are identified in the elderly population; only a few patients die 
because of AAA rupture prior to the age of 60. The incidence of the disease in the general 
population is 60/1000 inhabitants [4] and between 1.8% and 6.6% in autopsies studies. In 
studies of natural history of AAA the rate of aneurysm rupture and death could exceed 60% 
within 3 years of the initial diagnosis. [5]  
2. Pathogenesis 
The pathogenesis of aortic aneurismal disease is multifactorial. There is no consensus as to 
the cause of aortic aneurysms. Hypertension exists in about half of patients and is obviously 
an aggravating condition. Tertiary syphilis was once an important cause of aneurysms, 
particularly of the ascending thoracic aorta, but is a less common cause now.  
Genetic components have been identified in Marfan’s syndrome and Ehlers Danlos disease. 
Even in the most common, degenerative, form of aortic aneurysms there is a genetic 
component. Familial clustering of aortic aneurysms is evident as up to 20% of patients have 
one or more first-degree relatives who have also suffered from the disease.[6] More studies 
are clearly needed to establish details of the genetic interplay in aortic aneurysms. 
At times, an aneurysm may be caused by an extrinsic factor, such as an infection (micotic 
aneurysm) or trauma (pseudoaneurysm). 
Traditional views states that most aneurysms were caused by degenerative atherosclerotic 
disease but it affects different layers of the aortic wall. Atherosclerosis mainly affects the 
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intima, causing occlusive disease, while aortic aneurysm is a disease of the media and 
adventitia. They are distinct conditions that nonetheless often occur together.  
Histologically, AAAs are characterized by chronic inflammation with destruction of the 
extracellular matrix, remodelling of the wall layers, and reduction in number of smooth 
muscle cells. The effectors of destruction are a group of enzymes capable of degrading the 
major connective tissue components: collagen, elastin, fibronectin, laminin and the 
proteoglycans.[7] The inflammatory  infiltrate consists of macrophages as well as T and B 
lymphocytes, which excrete proteases and elastases causing wall degradation.[8] The reason 
for this migration is unclear. 
Degradation of elastin has been associated with dilatation while rupture of the wall is 
related to collagen degradation. Experimental studies of elastase induced aneurysms 
indicate that an inflammatory reaction within the aortic media is crucial for aortic dilatation.  
In both clinical and experimental studies, metalloproteinases (MMP), one of the most 
prominent group of elastases, have emerged as playing a role in the development of aortic 
aneurysms. [9,10] The MMPs are inhibited by the family of tissue inhibitors of 
metalloproteinases (TIMPs), including TIMP-1 and TIMP-2. An imbalance between the 
activated MMPs and their natural inhibitors may be responsible for the destruction of the 
aortic wall. Therapeutic trials with doxycycline, a MMP inhibitor, are ongoing and preliminary 
results are encouraging with less progression of aneurysmal size in treated patients.[11] 
Commonly assessed in AAA are also proteins involved in, stimulated by or associated with 
thrombosis, for example, fibrinogen and D-dimer.[12] 
A human biopsy study has confirmed the association between the extent of inflammation of 
the aortic wall and aortic diameter.[13] Interleukin-6 (IL-6), metalloproteinase-9 (MMP-9- 
gelatinase B) and C-reactive protein (CRP) are markers of inflammatory processes and have 
all been associated with AAA pathogenesis [13,14,15] as well as collagen type IV, fibronectin 
and other matrix proteins. High levels of MMP-9 and MMP-3 have been found in abdominal 
aortic aneurysmal tissue. Levels of MMP-9 are associated with aneurysmal size. [14,16,17] 
Hovsepian et al. Reported that MMP-9 plasma levels appeared to directly reflect the amount 
of MMP-9 produced within aneurysm tissue. MMP-9 plasma levels also decreased 
substantially after surgical AAA repair.[18] 
Circulating concentrations of many kinds of biomarkers have been measured and compared 
in patients with abdominal aortic aneurysm (AAA) and subjects without AAA to assess 
their possible role in the pathogenesis or progression of AAA (Table 1). Circulating 
biomarkers could play a role in the diagnosis of AAA reflecting also the AAA activity in 
asymptomatic phases and may have a role in predicting subsequent progression and thus 
the prognosis of AAA. 
Most investigated potential biomarkers show either no correlation or a weak correlation 
with the clinical course of AAA. Few have any potential for clinical use. Another limitation 
is related to the fact that many biomarkers for AAA are not disease specific; most of them 
also are markers for atherosclerosis. 
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Biomarker 
Number of 
patients 
Summary of findings Author, year 
MMP-9 36 Plasma MMP-9 may predict the natural 
history of AAA 
Lindholt J. et 
al. 2000 
MMP-9, MMP-2 
TIMP-1, TIMP-2 
76 Both MMP-2 and 9 failed to show relevance as 
serum markers for aortic dilatation. 
Eugster T et 
al. 2005 
30 medium-
sized ruptured 
AAA 
30 large 
asymptomatic 
AAA (aAAA) 
AAA rupture is associated with higher levels 
of MMP-9 in the aortic wall. There is no 
association to TIMP-1 or TIMP-2 levels. MMP-
2 levels are positively, whereas MMP-9 levels 
are negatively correlated to aAAA. This may 
indicate that MMP-9 may have a determinant 
role in the AAA wall for the progression 
towards rupture, whereas MMP-2 pay a role 
for expansion. 
E. Petersen et 
al. 2002 [19] 
37 Plasma levels of MMP-9 can accurately 
discriminate between patients with and 
without an endoleak with both high sensitivity 
and specificity. Anterior-postreior aneurysmal 
diameter (Dmax) was significantly larger in the 
endoleak group, however, plasma MMP-9 
levels were not associated with Dmax or 
intraluminal thrombus volume. 
F.A.M.V.I. 
Hellenthal et 
al.2012 [20] 
MMP-9, MMP-1 52 non-
ruptured AAA 
16 ruptured 
AAA 
The concentrations of MMP1 and MMP9 were 
significantly elevated in the plasma of ruptured 
AAA compared with non-ruptured AAA. 
There was no significant correlation between 
AAA diameter and enzyme concentration 
within the ruptured and non-ruptured 
cohorts. 
W.R.W 
Wilson et al. 
2008 [21] 
P-Elastase 79 P-elastase was positively correlated with the 
mean annual AAA expansion rate. 
Lindholt J. Et 
al. 2003 
IFN-gamma 50 Elevated IFN-gamma concentrations seem to 
predict an increased rate of expansion in 
AAA. 
Junoven J et 
al. 1997 
TNF-alpha, IL-8 90 IL-8 and TNF-alpha can be used as 
endogenous markers of the process of AAA 
development. 
Treska V et al. 
2000 
IL-6 7 In multivariate analysis the level of IL-6 was 
independently correlated with aortic diameter
Rodhe LE et 
al 1999 
IL-6, MMP-9, 
CRP 
213 No correlation was found between levels of 
circulating IL-6, MMP-9, CRP and the 
expansion of small-diameter AAAs, 
indicating no clinical use of these markers in 
AAA surveillance. 
Karlsson L. Et 
al.2009 [22] 
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Biomarker 
Number of 
patients 
Summary of findings Author, year 
C-reactive Protein
(CRP) 
Sympt 52 
Ruptured 62 
No correlation. A significant elevation of CRP 
could be found in patients who presented 
symptoms or rupture of an AAA. 
Domanivits H 
et al.2002 
545 CRP levels are elevated in larger aneurysms 
but do not appear to be associated with rapid 
expansion. 
Norman P et 
al. 2004 
151 CRP did not correlate with size or expansion 
rate of AAA 
Lindholt J et 
al 2001 
Serum highly 
sensitive CRP 
39 Serum hsCRP is associated with aneurysmal 
size. 
Vainas T et al. 
2003 
CRP, alpha 1-
antitripsin 
35 AAA 
patients 
35 controls 
A positive correlation was found between 
CRP and AAA diameter and alpha 1-
antitripsin and AAA growth. Alpha 1-
antitripsin may be a promising biomarker of 
AAA growth. 
M. Vega de 
Ceniga et 
al.2009 [23] 
D-dimer, 
fibrinogen/fibrin 
36 The largest diameter of AAA is correlated 
with the preoperative levels of D-dimer and 
FDP 
Yamazuni K 
et al.1998 
834 cases with 
AAA and 6971 
controls for 
fibrinogen 
264 cases with 
AAA and 403 
controls for D-
dimer. 
Plasma fibrinogen and D-dimer 
concentrations are likely to be higher in cases 
with AAA than control subjects. Higher 
plasma fibrinogen and D-dimer 
concentrations may be associated with the 
presence of AAA. 
Takagi H. Et 
al. 2009 [12] 
110 patients 
with AAA 
110- controls 
Fibrinogen was positively correlated with 
AAA size (r =0.323; p<0.01) and the 
percentage of intra-luminal thrombus 
occupying the lumen (r =0.358; p<0.05). 
Al-Barjas et 
al. 2006 [24] 
Insulin-like 
Growth Factor 1  
(IGF-I) 
115 small AAAs Serum IGF-I, but not IGF-II, correlated 
positively with AAA size and AAA growth. 
IGF-I levels may serve as a novel biomarker 
for the natural history of AAA. 
 
J.S. Lindholt 
et al. 2011 [25] 
Table 1. Summary of published studies reporting the role of circulating biomarkers in the growth and 
rupture of AAA 
Active investigations continue to identify markers other than size that would predict a risk 
of rupture. Circulating biomarkers could also indicate optimal intervals between the 
surveillance intervals. Finally, the identification of biomarkers also may identify potential 
pathogenic pathways, and thus may open possibilities for pharmacological inhibition of 
growth, and provide a tool for monitoring this inhibition.[26] 
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In the future, extended longitudinal studies will be necessary to assess the true potential of 
matrix-turnover and other biomarkers. New methods, including proteomics and genome 
wide association studies, may identify new pathways and new potential biomarkers. 
3. Treatment  
Surgical repair was first reported in 1962 and still remains the treatment with the best long-
term results. The surgical technique is illustrated in Figure 1. It is a major surgical procedure 
done under general anaesthesia, usually consisting of a midline laparotomy and cross 
clamping of the aorta and iliac vessels. 
 
Figure 1. Open surgery technique for AAA 
The mortality of elective surgery is between 3 and 7%. These rates increase significantly in 
patients with comorbidities, particularly with coronary artery disease and carotid artery 
disease. Surgical results are impaired by chronic renal failure and COPD. 
Increasing age is an important adverse determinant of mortality in both ruptured and intact 
aneurysms. 
In the USA statistics indicate that more than 15000 deaths/year are caused by aneurysm 
rupture. 
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This is the reason why there are screening studies among the target population in order to 
save lives and decrease health costs. The great interest is to detect and treat the AAA before 
rupture but the problem is that most of them are asymptomatic.  
Because open surgery has non-negligible mortality and postoperative complications 
associated with a long hospital stay (10.8 days average) scientists tried to develop alternative 
methods to treat this disease addressing those cases with surgical high risk. 
Minimally invasive techniques were developed in order to exclude the aneurysm from the 
circulation and to provide a new circulator channel towards the legs. Potential applications 
of endovascular grafts have been found in all areas of vascular surgery but their use for 
aortic aneurysms was the first to be explored. Endovascular aneurysm repair (EVAR) is an 
alternative to open surgery in the management of AAA. Juan Parodi and colleagues 
performed the first endovascular aneurysm repair in Argentina in 1991 [27,28]. Two decades 
after, the technique has evolved immensely and new devices developed allowing to a 
greater number of patients to be treated with EVAR. Repair of aortic abdominal aneurysm 
(AAA) is performed to prevent progressive expansion and rupture. [27, 29 30]  
EVAR is progressively replacing open surgery and now accounts for more than half AAA 
repairs [31] as for example endovascular repair of AAA in Kaiser Hawaii Hospital (USA) 
was 50% in 2004 of the surgical activity.  
A study published in November 2011 identifies the rate of endovascular treatment for AAA 
in different countries during 2005-2009 (Figure 2), whose prospective data were included in  
 
 
 
Figure 2. Rate of EVAR in the management of AAA in different countries 
 
Abdominal Aortic Aneurysms – Actual Therapeutic Strategies 175 
the VASCUNET database [32]. The study shows a rapid and extensive implementation of 
the endovascular treatment, with the advent of studies with favourable results in this 
direction. 
EVAR in addition to the advantage of being a minimally invasive method and as such 
preferred by the patients, has many proven benefits compared with traditional open 
surgery: low rate of peri- and postoperative mortality and morbidity, shorter hospital stay, 
significantly reduced intraoperative blood loss and faster recovery. [33, 34, 35] One 
drawback is the significantly higher reintervention rate compared to open repair. 
4. Evidence base for EVAR 
In order to evaluate this new method there are registries [36] (retrospective studies) as: 
RETA (registry of endovascular treatment for aneurysms) in the UK, started in 1996 [37], 
EUROSTAR also started in 1996 [38], the Lifeline registry in the USA started in 1998 [39]. 
There are also randomized, controlled, multicenter trials: EVAR 1 and 2 initiated in 1999 and 
DREAM (Dutch randomized endovascular aneurysm management) started in 2000. 
In RETA, 31 UK centers submitted data. From January 1996 to December 1998 611 cases 
were enrolled. Four percent received an aortic tube device, 60% an aorto-iliac device and 
36% an aorto uni-iliac device with femoro-femoral crossover graft. The objectives were to 
assess early morbidity and mortality. Conversion to open repair was in 5% of cases. The 
overall mortality was 7% vs. 12% for open surgery. Endoleaks were more common in larger 
aneurysms (2% if aneurysm diameter was < 6 cm and 10% if it was > 6 cm) [37]. 
EUROSTAR (European collaboration on stent graft techniques for aortic aneurysm repair) 
Registry was established in 1996. The results were published in JVS in October 2000, 88 
European centers have contributed, enrolling 2464 patients with a main follow up of 12.19 
months. The 30 days mortality was 3.1%. The cumulative risk of late conversion was 
2.1%/year and of rupture 1%/year. The significant factors for rupture were: type I endoleak, 
type III endoleak, graft migration and postoperative kinking of the endograft. The feasibility 
rate of the procedure was 97% of patients using first and second generation devices. The rate 
of late failure of the devices was 3%/year.[38,40] 
The Lifeline registry was established in 1998 in the USA and the results were published in 
JVS in July 2005. The end point was to evaluate the long-term outcome of patients treated 
with EVAR using 5 devices who had FDA approval (Guidant Ancure, Medtronic AneuRx, 
Gore Excluder, Endologix PowerLink, Cook Zenith). It enrolled 2664 patients with EVAR vs. 
334 open repair control patients. The 30 day mortality of EVAR was 1.7% which was not 
different from surgical control (1.4%), this in spite of the EVAR patients who were 
significantly older and sicker (more comorbidities). The risk of rupture of the aneurysm 
after EVAR was 3 times higher (2.1%) in women than in men (0.7%). The risk of rupture of 
the AAA remained stable over a 6 year period at a level of 1%/year. The surgical conversion 
rate was 3% at a year and 5% at 6 years (low). All this shows that EVAR is safe and effective 
in preventing aneurysm rupture and avoiding AAA related death. [39] 
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The most known and discussed randomized, controlled, multicentre trials are the UK 
EVAR1 and 2 which were initiated in 1999 and published in “The Lancet” in 2004 [41] and 
2005 [42]. EVAR 1 compares endovascular procedures vs. open repair. A great number of 
patients (2068) were enrolled, aged over 60 years with a non ruptured AAA and who had an 
aneurysm of more than 5.5 cm in CT scan diameter. Morphological suitability for EVAR [43] 
and choice of the stent graft was decided by each center (41 centers enrolled). The 30-day 
mortality rate was 1.7% compared with 4.7% for open surgery. The secondary interventions 
were 9.8 for EVAR and 5.8 for open repair. Patients unfit for open repair because of 
significant comorbidities were randomized for EVAR or best medical treatment in the EVAR 
2 trial. 338 patients aged 60 years or older with an AAA >5.5 cm in diameter were enrolled. 
The primary end point was aneurysm related mortality, postoperative complications and 
hospital costs. The risk of rupture is 25%/year for aneurysms with diameters greater than 6 
cm. The 30-day mortality was 9% in EVAR group and in the non intervention group was 9.0 
/ 100 pers / year. There was no significant difference between the EVAR group and non 
intervention group for all cause mortality. 
The DREAM trial initiated in 2000 enrolled 345 patients considered suitable for both types of 
treatment. The 30-day mortality after EVAR was 1.2% compared with 4.6% for open 
surgery. The results were published in 2002 in Journal of Cardiovascular Surgery [44, 45]. 
The Veteran open vs. endovascular repair (OVER) trial started enrollment in October 2002 in 
the US. It was design to enroll 5 years followed by a 4 year follow up. In total a 9 years 
survey. The primary outcome is long-term survival and secondary outcomes included 
morbidity, procedure failures and need for secondary procedures and costs. 33 centers are 
participating, 684 patients were enrolled in September 2006 and the investigators expect 900 
by the end of the study. Patients enrolled had aneurysms of more than 5cm and were 
candidates for both procedural types. [46] 
The French trial “Anevrisme Chirurgie vs Endoprothese” (ACE) also had the same enrollment 
conditions and primary and secondary end points. 
In OVER and ACE trials were used newer devices for treating AAA than those used in 
EVAR 1 and DREAM (procedures performed between 1999-2003)[46]. The Gore Excluder 
and Medtronic AneuRx represent 2/3 from the devices used in OVER compared with only 
11% used in EVAR 1. 
Speaking about costs the shorter ITU and hospital stay in the EVAR group, with initial 
comparable costs, the cost per patient over 4 years is higher in EVAR because the cost of the 
endograft and subsequent of secondary interventions (Figure 3)[43]. 
In summary, EVAR has lower perioperative mortality but there is no difference in long term 
overall mortality. This procedure is associated with 10% risk of aneurysm related 
complications/ year, but they can be solved by further endovascular reinterventions [43]. 
EVAR is a safe, effective and durable treatment for infrarenal aortic aneurysms with suitable 
anatomy. 
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Figure 3. EVAR costs per patient ( modified after [43]) 
5. Indications and anatomical suitability 
Patient selection is an important element of successful EVAR. We should carefully 
investigate and consider the anatomy of the abdominal aorta, the relationship with the 
emergence of the renal arteries, the calibre, tortuosity and calcifications of the iliac arteries. 
The misevaluation of morphological aspects can lead to immediate or late failure of the 
procedure. With the refinement of medical devices (multislice CT scan with 3D 
reconstruction, substraction angiography, sophisticated computer data analysis), we can 
detect all the morphological modifications in the aneurismal area in segments immediately 
adjacent.  
The Clinical Practice Guidelines of the European Society for Vascular Surgery on the 
management of AAA, published in April 2011, sets out a series of recommendations in all 
aspects of diagnosis and management strategies of AAA (Figure 4,5) [47]. 
There is a consensus that in the case of small aneurysms, with a diameter between 3.0-3.9 
cm, the risk of rupture in negligible. Therefore, these aneurysms do not require surgery, 
supervision by Doppler Ultrasound at regular intervals being sufficient. The management of 
the AAA with a diameter between 4.0 – 5.5 was determined by two multicenter, 
randomised, controlled studies, that compared the natural evolution of these aneurysms 
versus early intervention: UK Small Aneurysm Trial (UKSAT) and American Aneurysm 
Detection and Management Study (ADAM) respectively [48, 49] and a smaller study, that 
compared endovascular treatment versus surveillance, the CAESAR study [50]. The 
PIVOTAL study including aneurysms with diameters between 4.0- 5.0 cm compared the 
endovascular treatment versus Doppler Ultrasound surveillance [51]. 
Medium-term results of these studies did not indicate a statistically significant difference in 
terms of overall mortality at 5 years, the results being similar in the long-term, at 12 years  
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Figure 4. Management strategy of AAA according to the size of the aneurysm (modified after [47]) 
 
 
Figure 5. Management of large aneurysms, with a diameter ≥5,5 cm (modified after [47]) 
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[48, 52]. The rupture rate of the aneurysms was 1% in the surveillance group and the overall 
mortality rate was 5,6% in the early intervention group. 
The results of the above mentioned large studies, UKSAT and ADAM were recently included 
in the COCHRANE study, that underlines the safety and through this the benefits of the 
Doppler ultrasound surveillance of the AAA with a diameter between 4.0 and 5.5 cm [53]. 
Performing Doppler Ultrasound surveillance of small aneurysms (4.0-5.5 cm) is safe and 
recommended for asymptomatic aneurysms. If the aneurysm reaches the 5.5 cm diameter 
limit, measured by Doppler ultrasound (in male patients), it becomes symptomatic or there 
is an annual diameter increase of >1cm/year, the patient must be immediately referred for 
further investigation to the specialised vascular surgery department. 
As highlighted, the diameter of the AAA establishes the moment for intervention, but this 
criteria alone is not enough to establish the indication for the endovascular treatment of the 
AAA. With new treatment methods new complications occur, requiring further 
investigations in order to assess the feasibility of the AAA for EVAR. The morphological 
criteria of the AAA are the ones that can establish or exclude the indication of EVAR. The 
failure to comply with these criteria, requested also in the instruction manuals of the 
endoprostheses currently on the market may lead to the increase of the peri- and 
postoperative complication, reintervention and post-EVAR mortality rate. 
An average 34% of AAA is not eligible for EVAR, most of them because of an adverse 
morphology. [54] 
The universal classification system defines the aneurysm in relation with the origin of renal 
arteries:  
 infrarenal, with a segment of normal (undilated) aorta named neck  
 pararenal or juxtarenal, when aneurysm originate just after the renals 
 suprarenal, the aneurysm includes the origin of renals or above without involvement of 
the superior mesenteric artery  
Another classification employed for EUROSTAR and DREAM trials is shown in figure 6, 
taking into account the distance from the renals and the bifurcation of the aorta as well as 
the involvement of iliac arteries (the common iliac artery, arriving or not to the bifurcation 
of iliac arteries, occlusion or stenosis of the common iliac arteries). 
The French system proposed by Kieffer & Chiche (2005) is also based on the distal extension 
of the aneurysm and is comparable with the EUROSTAR classification (Type I-V). 
The proximal neck is by far one of the most important anatomic finding in planning an 
endovascular procedure. It can be classified as shown in figure 7. 
The diameter of the neck, its length, shape and angulation are to be considered. Aortic neck 
angulation is defined as the angle between the axes of the proximal infrarenal aorta and the 
longitudinal axis of the aneurysm. It is classified as: mild < 40 degrees, moderate < 60dgr, 
and severe > 60dgr.  
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Figure 6. Classification of AAA (modified after [40]) 
 
Figure 7. Morphology of the aortic neck (modified after [40]) 
 
Figure 8. Preoperative measurements (EUROSTAR) 
   A                    B                      C                      D                     E                      F
Straight                 Tapered            Reversed tapered     Angulated <30°               Bulge 
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The neck is the place where the endoprotheses are fixed and sealed. Seal is the apposition of 
the outer surface of the endograft to the luminal surface of the aorta in order to exclude the 
aneurysm sac from the systemic pressure. Fixation is the counterforce that prevents 
migration and helps to maintain seal. 
Concerning the iliac arteries, the landing zone of the majority of grafts, we are interested in 
patency and diameter, length of the common iliac artery, shape or aneurismal, angulation or 
tortuosity and calcifications. 
Figure 8 shows a preoperative scheme for planning an endovascular repair showing all the 
anatomical features discussed above.(after [40]) 
5. Types of endoprostheses in use  
The grafts are classified in different manners. From the anatomic point of view, they can be: 
bifurcated (Ao bi-iliac), Ao – uni-iliac and tube (for Ao – Aortic – these were the most used, 
but now they are out of the market). They can be modular (most of them) or unibody 
(Powerlink). 
Figure 9 shows the images of some endoprosthesis in use today: modular (a,b,c) and 
unibody (d). 
 
Figure 9. Most used endoprosthesis 
The modular devices have at least two component grafts. The main body deployed on the 
neck of the aneurysm (“hanging from the Aorta”) and the two legs that arrives on the common 
iliac arteries. The unibody prostheses build up the endoluminal channel from the bottom to 
the top, sitting on the aortic bifurcation (concept of anatomical fixation) [55]. This prevents 
distal migration of the endoprostheses. 
a) Anaconda                 b) Talent          c) Zenith    d) Powerlink 
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The characteristics of the most used endografts [56, 57] are shown in the table 2: 
 
Endograft characteristics
Device Material
Confi-
guration
Deployment Fixation 
Aortic 
graft  
diam. 
Iliac 
graft 
diam. 
Supra-
renal 
stent 
Zenith 
(Cook) 
Polyester Modular
Self-
expanding 
Compression-
fit and barbs 
22-36 8-24 Yes 
Talent 
(Medtronic) 
Polyester Modular
Self-
expanding 
Compression-
fit 
24-34 8-24 Yes 
Excluder 
(Gore) 
ePTFE Modular
Self-
expanding 
Compression-
fit and 
anchors 
23/26/28.5
12-
14.5 
No 
Anaconda 
(Terumo) 
Twilleave Modular
Self-
expanding 
Compression-
fit and hooks
19.5-34 9-18 No 
Powerlink 
(Endologix) 
ePTFE 
One-
piece 
Self-
expanding 
Compression-
fit 
25/28 16 Optional 
E-Vita 
(Jotec) 
Polyester Modular
Self-
expanding 
Compression-
fit 
24/34 14-26 yes 
Table 2. The characteristics of the most used endografts [56, 57]  
The characteristics of an ideal stent graft are: 
 Low overall cost, 
 Stent-graft size ranging,  
 Long durability (metallic ultrastructure + graft material), 
 Good biocompatibility and sealing capacity, 
 Delivery device flexibility, lowest delivery device size, 
 Radial force stability, 
 Customization  
The new results of the endovascular management of AAA (by type of endograft) are shown 
in table 3 (retrospective or prospective studies) published in 2010 [58-63]. 
EVAR is not a procedure without complications[64-66]. One of the most redoubtable are the 
endoleak [67]. They are defined as persistence of the blood flow outside the lumen of the 
endograft, but within the aneurismal sac [68]. An endoleak may perfuse the aneurysm sac 
leading to aneurysm expansion and may be rupture. It represents the inability to obtain or 
maintain secure seal between the aortic wall and the graft [1]. The incidence of endoleaks is 
in range of 14%. They are classified in four types (from I to IV) [see the table 4 [1] modified]. 
The technique of introduction and deployment of the endograft is shown in figure 10. The 
access sites are the two femoral arteries. The anaesthesia required is general anaesthesia or 
loco-regional (peridural) [69]. 
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Device Author Study Type
No 
cases
Period 
Outcome
Clinical 
success Peri OP 
mortality 
Limb 
patency 
24months 
Anaconda 
(Terumo) 
Freyrie [58]
Prospective 
single center
127 2005-2009 0 96,7 100 
Excluder 
(Gore) 
Ghotbi [59]
Retro-
spective 
100 2006-2009 0 100 100 
Endourant 
(Medtronic) 
Bockler 
[60] 
“Engage” 
prospective 
180 2008-2009 1,7 100 99,4 
Zenith 
(Cook) 
Bequemin 
[61] 
Prospective 
single center
212 2000-2004 0,9  99,5 
Powerlink 
(Endologix) 
Krajcer [62]
Prospective 
single center
50 2008-2010 0 100 98 
Evita 
(Jotec) 
Moula-
kakis [63] 
Retro-
spective 
single center
30 2008-2009 0 100 100 
Table 3.  
I. Attachment site leaks
- Proximal end of endograft 
- Distal end of endograft 
- Iliac occlude [plug] 
II. Branch leaks (collateral back bleeding)
- simple (one) 
- complex (two or more branches) 
III. Graft defect (modular dissociation)
- minor < 2mm 
- major ≥ 2 mm 
IV. Graft material porosity
Table 4. Classification of Endoleaks [1] 
Both types I and III are significant risk factors for late aneurysm rupture and should be treated. Types II 
are considered benign and type IV usually resolves spontaneously during the post procedure period. 
With this procedure, we can reduce blood lost (using also devices like the cell-saver) and 
consequent transfusion requirement, ITU and hospital stay. More patients can be treated 
where comorbidity previously excluded them. The follow-up is done by using CT scan 
exams at 1, 3, 6 and 12 months after the procedure. There are changes in the aneurysm 
volume after endovascular repair in terms of shrinking [61,70,71]. 
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Figure 10. Schema of modular endograft deployment 
6. Operative data and results (Nürnberg experience and Army’s Clinic 
Center for Cardiovascular Diseases, Bucharest) 
We have conducted a prospective, randomized study starting from 1994, including patients 
diagnosed with infrarenal aortic aneurysm with a diameter ≥ 5.5 cm. The purpose of this 
study was to assess the results of abdominal aortic aneurysm repair of two large volume 
centers, in terms of perioperative, early and midterm complications, reintervention rate and 
mortality. 
Exclusion criteria were: Presence of comorbidities that could affect the postoperative 
surveillance: Renal insufficiency with serum creatinine level > 1.5 mg/dl, serum urea > 50 
mg/dl, mental illnesses, hypersensitivity to the contrast agent, unable to be followed as an 
outpatient, claustrophobia, the presence of previously implanted metal devices: pace 
makers, mechanical heart valves etc.  
Collected data: The collected data was entered in an excel database. Patient demographics 
and other variables were introduced, like:  
 Qualitative variables: endovascular treatment indication, name and type of prosthesis 
used, vascular access method (percutaneous puncture of the femoral artery, surgical 
incision, temporary iliac conduit), type of anaesthesia, postoperative complications 
occurred (endoleak, endograft migration, kinking)  
 Continuous quantitative variables: pre- and postoperative data on aneurysm morphology 
determined by CTA preoperatively and by DUS and CTA postoperatively (maximal 
anterior-posterior and transverse dimension of the aneurysm sac, length of the aneurysm, 
size and morphological changes of the aneurysm neck, the distance between the 
aneurysm and the emergence of the renal arteries, common iliac artery length and 
diameter) duration of intervention, the amount of blood loss, reinterventions. 
In Nürnberg, we started endovascular treatment in 1994 with Ancure stent-graft. In our 14–
years experience of 1502 cases (ending dec. 2007) we have used 13 different endografts. 
 
Abdominal Aortic Aneurysms – Actual Therapeutic Strategies 185 
From them, 1391 were men and 111 women, with a mean age of 71.5 years (41-98). The 
median follow up was 41 months (1.0-98) and the AAA had a mean diameter of 52.4 cm. For 
short and angulated necks we prefer now the Powerlink (Irvine, CA, USA) device, which we 
have started in 1999 [72]. Ending Dec. 2007, 519 cases were done using Powerlink grafts.  
The 30 day mortality was 1.7%. The total reintervention rate was 5.3%, while no distal 
migration, conversion or post Evar rupture occurred. Using this device we arrive to treat 
endovascularly 85-90% of the infrarenal AAAs in our hospital. 
At the Army's Clinic Center for Cardiovascular Diseases, Bucharest, between July 2008 - 
December 2010, 17 patients underwent EVAR for Abdominal Aortic Aneurysm (AAA), with 
age range between 49-82 years and aneurysm mean diameter 7.1 ± 0,5 cm (range: 5.4 – 8.2 
cm) [73]. 
The preoperative assessment was achieved using Doppler Ultrasound (DUS), Multislice CT, 
and sometimes DSA (Digital Substraction Angiography). The measurements for the graft 
type and dimensions were done according to the Multislice CT analyzing. (Figure 11 a, b 
and c). 
 
Figure 11. a), b) Preoperative multislice CT of a infrarenal AAA, with a suitable anatomy (2.2 cm neck 
length, no involvement of iliac arteries, 5.3 cm transversal diameter. c) Preoperative substraction 
angiography – with a catheter measuring the real length of the Aorta 
The EVAR devices used for these patients were:  
- Anaconda (Vascutek, Terumo, Inchinnan, Scotland)-1 patient 
- Talent (Medtronic, Santa Rosa, CA, USA) -3 patients 
- Powerlink (Endologix, Irvine,CA, USA) – 7 patients 
- EVITA (Iotec, Hechingen, Germany)- 6 patients.  
a) b) c) 
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The access was bifemoral, through open femoral incision, with peridural anaesthesia.  
Until present they followed our institutions surveillance protocol, that consisted of both 
DUS and CTA examination at 1,3,6,12 months and yearly after EVAR. None of them went 
through all of the surveillance dates (due to high examination costs) but each has at least 3 
sets of examinations, one set consisting of both DUS and CTA.  
The technical success rate was 100%, with no perioperative and postoperative complications 
regarding endoleaks, graft migration and graft component failure. 4 patients had access site 
complications, 3 had groin haematomas that reabsorbed after approximately 1 week and 1 
returned with an infection at the level of the inguinal incision, which resolved also with 
wound care. There were no conversions to open repair up to present. The stent-graft 
patency rate at this point at these patients is 100%. 
Figures 12 and 13 show two cases of AAAs treated with two different devices and two 
different strategies: Anaconda (Terumo) device and Powerlink (Endologix) stent graft. 
 
 
Figure 12. AAA treated with Powerlink Endograft a) Proximal extension; b) Main body of the stent-
graft; c) The two iliac segments of Powerlink® system 
 
 
Figure 13. a) Anaconda endograft for infrarenal abdominal aortic aneurysm therapy; b) Angiography 
at the beginning of the procedure; c) The main body of the stent; d) The two iliac Anaconda system  
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7. Particular situations 
7.1. Ruptured AAA 
In open repair of ruptured AAAs the perioperative mortality ranges between 30% and 
65%[74,75].Emergency EVAR is an alternative in selected patients with RAAA. The first report 
of emergency repair of an AAA was in 1994. Possible advantages are avoiding general 
anesthesia and laparotomy. Though a major inconvenient is the need of an endovascular team 
to be available at all times and to assess the preoperative CT scan in order to choose the size of 
the device. Following the emergent CT scan the anatomical suitability for EVAR was evaluated, 
including the access vessels [76].Several modular or unibody devices can be used but aorto-uni-
iliac devices with subsequent fem-fem crossover bypass and occlusion of contralateral iliac 
artery could also be used. Veith [77] reported in 2009 a series of 57 patients with R-AAA treated 
endovascularly. 25 of these patients received the VI graft (distributed in Europe by Datascope-
Maquet), made of a large Palmaz stent attached to a PTFE graft. This graft is used in 
aortofemoral configuration. This graft is “a one size fits most “because the proximal diameter 
can vary from 20 to27mm depending on the balloon inflation pressure. The periprocedural 
mortality was only 12,3%,inspite of serious medical comorbidities of the patients. 
In the series reported by Kapma in 2005 on 253 patients treated with E-EVAR vs open 
surgery the perioperative mortality was lower (13%) in the Evar group compared with OR 
(30% p=0,021).According to the SVS practical guidelines [31] E-EVAR should be considered 
for treatment of a R-AAA, if anatomically feasible, with a strong level of recommendation 
and a moderate quality of evidence. 
7.2. Juxtarenal AAA  
Juxtarenal AAA have short (11-15mm), or very short (< 10mm) necks. The anatomically 
unsuitable AAAs has short and/or angulated necks. They have a high risk of stent graft 
distal migration and proximal type I endoleak, because the inability to provide a sufficient 
proximal landing zone to secure fixation and seal. The strategy for treating this challenging 
AAAs is to build up the endoluminal exclusion system from the aortic bifurcation to the 
renal artery level with suprarenal fixation. At Nürnberg Hospital we used the Powerlink 
unibody bifurcated stent graft with a long suprarenal cuff. A Palmaz stent can be used for 
proximal fixation in hostile necks (short necks with severe angulation). 
Suprarenal fixation does not lead to a significant increase of acute renal events (renal 
insufficiency, high blood pressure) compared with infrarenal fixation [72] 
Figure 14 shows an angiography of AAA treated with a Powerlink graft with suprarenal 
fixation; for better sealing a proximal ballooning at the end of the procedure was performed. 
7.3. AAA with iliac extension 
The iliac extension of the AAAs can put technical problems in choosing the graft, especially 
if the iliac aneurysm reaches the bifurcation of the iliac artery (fig.11a). In this situation, the  
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Figure 14. a) After suprarenal prox. Cuff; b) Proximal balloning. Fenestrated grafts are now available to 
treat juxtarenal AAA [78-80] 
leg of the graft should land on the external iliac artery, covering the hypogastric artery 
(post-operation complications can occur like buttock claudication). In the case of planning to 
cover one hypogastric artery, we should close the artery (by coiling for ex.) a few days 
before implanting the endograft, in order to prevent distal type II endoleak. 
Figure 15 shows a 72 year old patient treated at the Army's Center for Cardiovascular 
Diseases, using a Powerlink graft with left iliac graft extension - left hypogastric artery was 
occluded with coils 24h before the intervention. 
In order to preserve the hypogastric artery, custom made, fenestrated or branched 
endografts can be used. Although this procedure was performed to prevent pelvic ischemia, 
this is not always the case. Figure 16 presents a case of a 75 year old male patient with AAA  
 
Figure 15. Patient O.P., 72 years old, preoperative multislice CT; a) AAA with left iliac extension; b) 
multislice CT-Scan at 3 months after EVAR with PowerLink endoprosthesis; c) multislice CT-Scan 2 
years after EVAR with PowerLink endoprosthesis. 
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treated by EVAR with a fenestrated endograft that presented to our department with 
buttock claudication 6 months after EVAR. The performed angiography evidentiated an 
occluded right hypogastric artery. Conservative treatment with Vasaprostan 20μg was 
instituted with good results. 
 
Figure 16. 75 year old male patient with AAA treated by EVAR Completion angiography after EVAR 
using a fenestrated endograft for the right hypogastric artery. b) Angiography performed 6 months 
after the intervention showing an occluded right hypogastric artery. 
7.4. AAA and comorbidities: Coronary artery disease, carotid stenosis. 
It is well known today that cardiac complications of patients with AAAs treated 
endovascularly is between 3 to 7%[31]. In order to avoid useless coronarographic 
investigations , we have to identify clinical parameters to indicate prior myocardial 
revascularization (surgery or stenting). Kieffer and Coriat, in a study published in 1999, on 
270 patients operated for terminal Aorta pathology (aneurismal or stenotic) show an 
incidence of 55% of coronary stenosis in the AAA population which requires in 25% of cases 
myocardial revascularization. The risk factors which were identified were age >65 years and 
history of myocardial infarction. Stable angina with left main disease, or triple-vessel 
disease, as well as patients with two vessel disease that includes proximal LAD are 
candidates for preoperative coronary revascularization. The coronary intervention should 
be done prior to AAA treatment in one month interval. However the perioperative mortality 
can arrive to 25% (with extracorporeal circulation and cardiac arrest)  
The carotid stenosis with a hemodynamic impact has a prevalence of 10.5%in the AAA 
patients. 
Coronary and/or carotid lesions, treated or not, represent a significant risk factor for 
postoperative death. For this, systematic preoperative screening is mandatory [81,82]. 
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Steinmetz published in 2008 an analysis of outcome after using high risk criteria selection to 
surgery vs. EVAR [83].The conclusion was that high risk criteria cannot be decisive in the 
choice of treatment.  
8. Future developments 
8.1. Totally percutaneous procedures 
Because local groin wound complications as a result of the exposure of the two common 
femoral arteries are not negligible [84], surgeons and engineers tried to develop alternative 
access techniques. One of them is the fully percutaneous procedure. The main device available 
is Perclose ProstarXL(Abbott). For technical success patient and device selection should be 
done. Severe femoral artery calcification, scarred groins, femoral artery aneurysms are 
contraindications for the use of these devices. The overall related complications were 4.4%. 
Among them infection and artery trombose are the most redoubtable. The hospital stay is 
shorter in patients undergoing P-EVAR (2.7 days vs. 3.5 days) compared with EVAR. In 
conclusion, P-EVAR appears safe and effective in selected patients. 
8.2. MRI devices 
A new research field in our days is based on the hypotheses that the endografts can be 
visualized and navigated in vivo solely under Rt-MRI(real time magnetic resonance 
imaging). MRI can provide immediate assessment of endograft apposition and aneurysm 
exclusion. MRI offers also better soft tissue visualization, detecting type I endoleaks by 
depiction of complex 3D anatomy. 
The technique is now applicable on murine models of AAA [85]. They have used a passive 
commercial endograft, image based on metal MRI artefacts, and active homemade endografts 
incorporating MRI receiver coils (antennae). Active devices proved to be most useful. The MRI 
images proved graft apposition and aneurysm exclusion. MRI imaging also permits 
immediate post-procedural anatomical and functional evaluation of the successful procedure. 
In conclusion, MRI may be equivalent or superior to computed tomography for procedure 
planning and surveillance of the endografts. Future development of active devices is 
required, in order to have a commercial graft that can be used in clinical testing and practice. 
9. Conclusions 
Our results show that in the modern era of abdominal aortic aneurysm treatment EVAR is 
an appropriate treatment for selected patients, especially those at high risk for open surgical 
repair. 
The future of EVAR as the potential gold standard for aortic aneurysm therapy rests upon 
the vision and creativity of both surgeons and technology innovators to realize the potential 
of endovascular interventions, and take them toward a broader and more effective portfolio 
of techniques and devices that will define the XXI-st Century Endovascular Aortic Surgery. 
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